BackCSPC Pharmaceutical Group Limited. Overview

CSPC Pharmaceutical Group Limited. Total Liabilities

CSPC Pharmaceutical Group Limited.'s total liabilities is $14B.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$13.53B
28.57% YoYΔ $3.01B vs prior year quarter

Peer average

Loading

CSPC Pharmaceutical Group Limited. Total Liabilities History

Loading

CSPC Pharmaceutical Group Limited. vs. peers: Total Liabilities Comparison

Loading

CSPC Pharmaceutical Group Limited. Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

CSPC Pharmaceutical Group Limited. (CSPCY) FAQ

CSPC Pharmaceutical Group Limited.'s total liabilities stands at $14B as of December 2025. That compares with $11B in the prior-year period — up 28.6% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

CSPC Pharmaceutical Group Limited. reported $14B in total liabilities versus $11B a year earlier — a 28.6% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $11B in the prior-year period — up 28.6% year over year. Sustained growth in total liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how CSPC Pharmaceutical Group Limited.'s total liabilities evolved across reporting periods, while the comparison chart places CSPCY next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total liabilities is commonly used to spot outliers. CSPC Pharmaceutical Group Limited.'s reading of $14B is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.